NCT00434187CompletedPhase 1
An Ascending Multiple Dose Study of the Safety, Tolerability and Pharmacokinetics of ERB-041 Administered Orally to Healthy, Female Japanese Subjects
Wyeth is now a wholly owned subsidiary of Pfizer1 site in 1 country24 target enrollmentStarted: August 1, 2006Last updated:
Conditions
Drugs
Trial Snapshot
- Phase
- Phase 1
- Status
- Completed
- Sponsor
- Enrollment
- 24
- Locations
- 1
- Primary Endpoint
- safety, pharmacokinetics
Study Overview
Brief Summary
The primary objective is evaluate the safety, tolerability, and pharmacokinetics of multiple doses of ERB-041, an investigational drug, in healthy, female Japanese subjects.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- Double
Eligibility Criteria
- Ages
- 20 Years to 45 Years (Adult)
- Sex
- Female
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Healthy as determined by the investigator on the basis of medical history and screening evaluations.
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
safety, pharmacokinetics
Secondary Outcomes
No secondary outcomes reported
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Completed
Phase 1
Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of MYO-029HealthyNCT00563810Wyeth is now a wholly owned subsidiary of Pfizer72
Terminated
Phase 1
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ABT-957 in Subjects With Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase InhibitorsAlzheimer's DiseaseNCT02220738AbbVie19
Terminated
Phase 1
A Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MK-5823 in Overweight or Obese Participants Who Are Healthy or Have Type 2 Diabetes Mellitus (MK-5823-002)Type 2 Diabetes MellitusNCT01614782Merck Sharp & Dohme LLC24
Completed
Phase 1
Study Evaluating the Pharmacokinetics of HCV-796 in Healthy Japanese MenHealthyNCT00385190Wyeth is now a wholly owned subsidiary of Pfizer24
Completed
Phase 1
A Study of MK-8189 in Participants With Schizophrenia (MK-8189-014)SchizophreniaNCT05406440Merck Sharp & Dohme LLC53